good to know…
fight dmd trial receives first fda orphan product grant
"We were thrilled to receive the first grant from the FDA Orphan Product Development program for a DMD trial."
MDA Annual Meeting Presentation: PREVENTING DUCHENNE MUSCULAR DYSTROPHY CARDIOMYOPATHY THROUGH ANTAGONISM OF THE THROMBOXANE PROSTANOID RECEPTOR: AN FDA FUNDED PHASE 2 CLINICAL TRIAL
1st FDA-funded DMD Study Now Recruiting Patients to Test Ifetroban
“Cumberland Pharmaceuticals is recruiting boys and men for a Phase 2 study evaluating the safety, efficacy, and duration of effect of its oral ifetroban therapy for cardiomyopathy — a disease of the heart muscle — linked to Duchenne muscular dystrophy (DMD).”
Cumberland announces new dmd program & fda grant award
"Cumberland announced a new DMD program supported by the FDA Orphan Product Development Clinical Trial program."
NIH-supported research survey to examine impact of COVID-19 on rare diseases community
“A new online survey launched by the National Institutes of Health-supported Rare Diseases Clinical Research Network (RDCRN) aims to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers.”
MUSCULAR DYSTROPHY NEWS TODAY
"MD News announces FDA’s award of $1M to Cumberland Pharmaceuticals to study the effect of ifetroban on heart disease associated with DMD."
Parent Project Muscular Dystrophy Ifetroban Resource Page
Information page and media library including previous presentations at the annual PPMD annual meeting since 2019.
PPMD 2023 - Research Row
Dr. Markham’s presentation of the interim analysis of the Fight DMD trial is at the 26:30 mark.